Evidence map›Paper›PMID 42063415›Full record

ArticleJournal of asthma and allergy2026

Stability of Type 2 Inflammation in a 12-Year Adult-Onset Asthma Follow-Up Study.

Ella Flinkman, Iida Vähätalo, Leena E Tuomisto, Lauri Lehtimäki, Onni Niemelä, Madeleine Rådinger, Bright I Nwaru, Selin Ercan, Mari Hämäläinen, Eeva Moilanen and 2 more

Abstract read
In one paragraph

Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ella FlinkmanFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Iida VähätaloFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.ORCID 0000-0003-0962-8446
Leena E TuomistoFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Lauri LehtimäkiFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.ORCID 0000-0003-1586-4998
Onni NiemeläFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Madeleine RådingerKrefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-0652-7378
Bright I NwaruKrefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-2876-6089
Selin ErcanKrefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Mari HämäläinenThe Immunopharmacology Research Group, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.
Eeva MoilanenThe Immunopharmacology Research Group, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.
Pinja Ilmarinen *Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Hannu Kankaanranta *Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.ORCID 0000-0001-5258-0906

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To assess the stability of T2 inflammation and clinical features associated with high or low T2 markers in adult-onset asthma. Patients and Methods: Seinäjoki Adult Asthma Study is a 12-year follow-up study including 256 patients diagnosed with new-onset adult asthma. Patients were grouped according to T2 marker status at baseline when steroid-naïve and at the 12-year follow-up after long-term inhaled corticosteroid (ICS) treatment. High T2 markers were defined at diagnosis by ≥1 of the following: blood eosinophils ≥0.30×10 Results: At diagnosis, 109 patients (66.5%) had high and 55 (33.5%) low T2 markers. Low T2 marker patients were older, had higher BMI, and higher Airway Questionnaire 20 scores. High T2 marker patients had greater reversibility of forced expiratory volume in 1 second. At follow-up, baseline low T2 marker patients had more comorbidities, non-respiratory medications and lower Asthma Control Test scores. Of patients, 76% remained in the low T2 marker group and 24% transitioned to the high T2 marker group; those who transitioned had higher BMI. Sixty-eight percent remained in the high T2 marker group and 32% transitioned to the low T2 marker group; those who transitioned were older, had more comorbidities, and more non-respiratory medications. No significant differences were observed between patients who transitioned and those remaining stable regarding lung function, asthma severity, control, exacerbations, or ICS use. Conclusion: T2 high and low markers of adult-onset asthma are largely stable over time. However, differences in comorbidities, non-respiratory medication, age, and BMI distinguish the groups significantly.

Indexed as

adult-onset asthmaendotypephenotypetype 2 inflammation

Identifiers

PMID42063415
PMCPMC13127434

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.